Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Focused Risk Assessment

The legacy of general health and science information has long served as a foundation for public understanding, drawing from structured, open-access data sources such as PubMed and institutional research databases. These repositories have historically provided curated, authoritative content on broad biomedical topics, enabling the extraction of core fields like researcher names, institutional affiliations, and study methodologies. In this context, the transition from general health awareness to a more focused occupational exposure concern begins with recognizing how such data can be repurposed. Specifically, the same principles of data extraction—identifying key entities, their relationships, and contextual modifiers—apply when shifting from a general health lens to one centered on specific chemical exposures in professional settings. The target query regarding Fosamax and osteonecrosis of the jaw exemplifies this pivot. While the legacy heritage emphasizes broad scientific communication, the bridge concept reframes this into an occupational exposure concern: examining how bisphosphonate compounds, such as those in Fosamax, may pose risks to individuals in manufacturing or healthcare environments. This transition leverages the same structured data approach—using core fields like exposure routes, occupational settings, and study populations—to generate targeted, evidence-informed content without delving into mechanistic claims. The focus remains on the shift from general health information to a precise, occupationally relevant risk assessment framework.

Bridging to Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed necrotic bone in the maxillofacial region, often occurring spontaneously but generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation involves non-healing extraction sockets, exposed bone, pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis.

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are thought to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates accumulate in bone, particularly in areas of high turnover like the jaw, and suppress bone remodeling. This suppression can impair the ability to repair microdamage and respond to local infections or trauma, such as tooth extraction. A multiscale characterization of jawbone has provided comprehensive information to help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Labeling

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 Osteonecrosis of the Jaw, stating that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning notes that the time to onset of symptoms varied from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also advises discontinuation if severe symptoms develop and notes that a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Furthermore, the label for Fosamax Plus D similarly lists risk factors and states that the risk of ONJ may increase with duration of exposure to bisphosphonates, and that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide guidance to clinicians and patients, though the adequacy may be debated given the rare but serious nature of ONJ.

Causation and Epidemiological Evidence

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The timeline between exposure and documented harm can vary widely. In clinical studies, the time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, population-level data provide a more nuanced picture. A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests that longer duration of exposure increases risk, but the absolute risk is small. Importantly, in placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as jaw pain were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not be captured in short-term trials. For affected patients, establishing causation requires considering the presence of other risk factors, such as dental procedures or concomitant medications. The label explicitly notes that ONJ is generally associated with tooth extraction and/or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Thus, while Fosamax use is a contributing factor, it often acts in concert with other triggers. The recurrence of symptoms upon rechallenge with bisphosphonates supports a causal role (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ should discontinue Fosamax and receive appropriate dental care, as most experience relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the evidence indicates that Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of dental procedures or other risk factors. The prescribing information includes warnings about this risk, but the absolute risk remains low. Causation is supported by temporal association, dose-response (duration), and recurrence upon rechallenge, though other contributing factors are often present.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption. A recognized adverse effect is osteonecrosis of the jaw (ONJ), characterized by exposed necrotic bone in the jaw, often after dental procedures. The risk increases with longer duration of use and in the presence of other risk factors such as tooth extraction, poor oral hygiene, or concomitant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How common is ONJ in Fosamax users?

ONJ is rare. A cohort study found absolute risks of approximately 0.05% after 5 years of treatment. The risk is threefold higher after 2-3 years and eightfold higher after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, chemotherapy, corticosteroids, poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does the Fosamax label warn about ONJ?

Yes, the prescribing information includes a specific warning under section 5.4 Osteonecrosis of the Jaw, noting that ONJ has been reported and advising discontinuation if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.